Acorda lower on safety concerns over its tozadenant

Acorda increases blood cell count monitoring in Phase 3 tozadenant program

Acorda Therapeutics lower on safety concerns over its Parkinson drug. See Stockwinners.com for details

Acorda Therapeutics (ACOR) announced that it has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson’s disease.

The company took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death.

Agranulocytosis is the absence of white blood cells, which fight infection.

The company also has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board and the United States Food and Drug Administration.

The Phase 3 program includes an ongoing pivotal efficacy and safety study and two long-term safety studies. Including the previously conducted Phase 2b study, approximately 890 patients have been exposed to tozadenant and 234 have been exposed to placebo.

This corresponds to approximately 300 patient years of tozadenant exposure and 75 patient-years of placebo.

There have been seven cases of sepsis, all in the tozadenant groups, five of which were fatal.

Four of the sepsis cases were associated with agranulocytosis, two had no white blood cell counts available at the time of the event and one had a high white blood cell count.

“We have taken these steps in the best interests of the safety of patients in the tozadenant studies, which is our top priority,” said Ron Cohen, M.D., Acorda’s President and CEO.

“Contingent on further input from the DSMB and FDA, we continue to expect to report efficacy and safety results of the double-blind Phase 3 study in the first quarter of 2018.”

ACOR closed at $28.20. It last traded at $17.40.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Leave a Reply

Your email address will not be published. Required fields are marked *